Abstract
The European Agency for the Evaluation of Medicinal Products (EMEA) was established in July 1993 to unify regulatory practices and improve market access within the European Union (EU). In February 1995, the EMEA implemented the centralized procedure for drug approval within the EU. The current study explores the history, goals, and implementation of the centralized procedure. We examine the time to obtain product marketing authorization for products that have gone through the process relative to the goals set for the program at its inception, and we compare approval times for a group of products that have been approved by both the EMEA and the United States Food and Drug Administration (FDA). Our data indicate that the goals established by the EMEA for the timeliness of application review have generally been met. Moreover, mean approval times for products approved by both the EMEA and the FDA were similar.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
30 December 2000
Volume 33, Issue 4 (1999) of the Drug Information Journal contains the following typographical errors in “The European Agency for the Evaluation of Medicinal Products’ Centralized Procedure for Product Approval: Current Status” by Elaine M. Healy and Kenneth I. Kaitin
References
Friedel E, Freundlich M. European Community harmonization of the licencing and manufacturing of medicinal products. Food Drug Law J. 1994;49(1):141–170.
European Agency for the Evaluation of Medicinal Products. Work programme 1997–98—EMEA. Luxembourg: Office for Official Publications of the European Community; 1997.
Currie WJC, Löfgren M. A Practical Guide to the EMEA. Waltham MA: Parexel; 1996.
Bass R. Why have targets for the review process? The view of the EMEA. Improving the Regulatory Review Process: Assessing Performance and Setting Targets. Proceedings of a CMR International Workshop held at Nuffield Priory, Nuffield, UK, January 1997. McAuslane N, Walker S, editors. Dordrecht: Boston, Kluwer; 1997.
Shulman SR, Brown JS. The Food and Drug Administration’s early access and fast-track approval initiatives: how have they worked? Food Drug Law J. 1995;50(4):503–531.
European Agency for the Evaluation of Medicinal Products. Second General Report 1996. Luxembourg: Office for Official Publications of the European Community, 1997. European Agency for the Evaluation of Medicinal Products. Third General Report 1997. Luxembourg: Office for Official Publications of the European Community; 1997.
Sauer F. A new and fast drug approval system in Europe. Drug Inf J. 1997;31(1):1–6.
Europe Should Move to Centralized Review of All Drugs—CPMP’s Winkler. Pink Sheet. November 30, 1998;60(48):17–18.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Healy, E.M., Kaitin, K.I. The European Agency for the Evaluation of Medicinal Products’ Centralized Procedure for Product Approval: Current Status. Ther Innov Regul Sci 33, 969–978 (1999). https://doi.org/10.1177/009286159903300401
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159903300401